NCT04340687View on ClinicalTrials.gov

Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing PEP

CompletedOBSERVATIONAL

Enrollment

664

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

March 1, 2020

Study Completion Date

March 1, 2020

Conditions

Healthy

Interventions

DEVICE

Pancreatic duct stenting

A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice

Trial Locations (1)

710032

Xijing Hospital of Digestive Diseases, Xi'an

All Listed Sponsors

lead

Air Force Military Medical University, China

OTHER

NCT04340687 - Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing PEP | Biotech Hunter | Biotech Hunter